Risk attitude and personality in people with multiple sclerosis facing the choice of different disease-modifying therapy scenarios.

Decision-making Disease-modifying therapies Multiple sclerosis Personality Risk attitude Shared decision-making

Journal

Journal of the neurological sciences
ISSN: 1878-5883
Titre abrégé: J Neurol Sci
Pays: Netherlands
ID NLM: 0375403

Informations de publication

Date de publication:
15 Oct 2020
Historique:
received: 13 01 2020
revised: 23 07 2020
accepted: 24 07 2020
pubmed: 9 8 2020
medline: 15 5 2021
entrez: 9 8 2020
Statut: ppublish

Résumé

As available disease-modifying therapies (DMTs) increase, evaluating benefit/risk presents greater difficulties, requiring people with MS (PwMS) to play crucial roles in choosing treatment. Although individual attitude toward risk may predict this evaluation, its relation to personality is little studied in MS literature. To prospectively assess risk attitudes and personality traits of PwMS choosing a DMT. In three Italian MS centers (2012-2015), 420 PwMS completed an ad hoc questionnaire on socio-demographic variables, personality, and standard-gamble questions, to evaluate MS- and DMT-related risks through two hypothetical drug scenarios. We assessed the influence of previously collected socio-demographic/clinical characteristics, and personality factors on risk attitude. Almost half of participants were mainly concerned about progressive multifocal leukoencephalopathy; <25% about relapses. Median acceptable risk of death for both hypothetical drug scenarios was 1:10,000; 19-20% would not take any risk related to DMT. Regression analysis revealed that being male, more educated, and with higher impulsivity/sensation-seeking propensity was significantly associated with a higher risk attitude. Both socio-demographic and personality factors affect risk attitude of PwMS facing different DMT scenarios. These findings could affect the shared decision-making process in selecting best treatment option for PwMS.

Sections du résumé

BACKGROUND BACKGROUND
As available disease-modifying therapies (DMTs) increase, evaluating benefit/risk presents greater difficulties, requiring people with MS (PwMS) to play crucial roles in choosing treatment. Although individual attitude toward risk may predict this evaluation, its relation to personality is little studied in MS literature.
OBJECTIVE OBJECTIVE
To prospectively assess risk attitudes and personality traits of PwMS choosing a DMT.
METHODS METHODS
In three Italian MS centers (2012-2015), 420 PwMS completed an ad hoc questionnaire on socio-demographic variables, personality, and standard-gamble questions, to evaluate MS- and DMT-related risks through two hypothetical drug scenarios. We assessed the influence of previously collected socio-demographic/clinical characteristics, and personality factors on risk attitude.
RESULTS RESULTS
Almost half of participants were mainly concerned about progressive multifocal leukoencephalopathy; <25% about relapses. Median acceptable risk of death for both hypothetical drug scenarios was 1:10,000; 19-20% would not take any risk related to DMT. Regression analysis revealed that being male, more educated, and with higher impulsivity/sensation-seeking propensity was significantly associated with a higher risk attitude.
CONCLUSIONS CONCLUSIONS
Both socio-demographic and personality factors affect risk attitude of PwMS facing different DMT scenarios. These findings could affect the shared decision-making process in selecting best treatment option for PwMS.

Identifiants

pubmed: 32763510
pii: S0022-510X(20)30401-9
doi: 10.1016/j.jns.2020.117064
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

117064

Informations de copyright

Copyright © 2020 Elsevier B.V. All rights reserved.

Auteurs

Eleonora Minacapelli (E)

Department of Neurology, Psychology Unit, San Raffaele Hospital Scientific Institute, Milan, Italy.

Andrea Giordano (A)

Unit of Neuroepidemiology, Fondazione IRCCS Istituto Neurologico Carlo Besta, Milan, Italy; Department of Psychology, University of Turin, Turin, Italy.

Monica Falautano (M)

Department of Neurology, Psychology Unit, San Raffaele Hospital Scientific Institute, Milan, Italy.

Francesca Sangalli (F)

Department of Neurology, San Raffaele Hospital Scientific Institute, Milan, Italy.

Erika Pietrolongo (E)

Department of Neuroscience and Imaging, University G. D'Annunzio, Chieti, Italy.

Lorena Lorefice (L)

Multiple Sclerosis Centre, Binaghi Hospital, ATS Sardegna, Cagliari, Italy.

Eleonora Cocco (E)

Multiple Sclerosis Centre, Binaghi Hospital, ATS Sardegna, Cagliari, Italy; Department of Medical Science and Public Health, University of Cagliari, Cagliari, Italy.

Alessandra Lugaresi (A)

UOSI Riabilitazione Sclerosi Multipla, IRCCS Istituto delle Scienze Neurologiche di Bologna, Bologna, Italy; Department of Biomedical and Neuromotor Sciences, University of Bologna, Italy.

Giancarlo Comi (G)

Institute of Experimental Neurology (INSPE), San Raffaele Hospital Scientific Institute, Milan, Italy.

Massimo Filippi (M)

Department of Neurology, San Raffaele Hospital Scientific Institute, Milan, Italy; Institute of Experimental Neurology (INSPE), San Raffaele Hospital Scientific Institute, Milan, Italy; Vita-Salute San Raffaele University, Milan, Italy.

Vittorio Martinelli (V)

Department of Neurology, San Raffaele Hospital Scientific Institute, Milan, Italy. Electronic address: martinelli.vittorio@hsr.it.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH